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Introduction 
 Dengue disease is one of the current major public health 
affairs and is endemic in the Americas, southern Europe, 
North Africa, the eastern Mediterranean, Asia, Australia, 
various islands in the Indian Ocean, the south and the 
central pacific and the Caribbean [12, 29, 41]. Approximately, 
2.5 billion people facing risk and it are predicted 
that this number will increase as transmission spreads to 
neighboring geographic regions [11, 13]. The World Health 
Organization (WHO) estimated of 100 million cases of 
dengue fever (DF) occurs annually [11]. In Malaysia, DF 
was reported as early as 1901 and the first report of the DF 
with hemorrhagic symptoms was made in 1962 [30, 34, 
36]. In 1973, the first major outbreak of dengue hemorrhagic 
fever (DHF) (45 cases) was reported [39]. Since that 
time, the increase of dengue cases in Malaysia has been 
very significant, e.g., 19,544 cases with 50 deaths reported 
in 1997, and then increased to 27,373 dengue cases with 58 
deaths in 1998 [1, 9, 34]. Recently, from 2004 to 2008, the 
number of dengue cases reported in Malaysia has increased 
from 33,895 (102 deaths) to 49,335 (112 deaths) [28]. 
 Dengue virus is considered as arthropod-borne virus 
due its transmission cycle between Aedes mosquitoes and humans [41]. Dengue virus consists of four serotypes 
(DEN1, DEN2, DEN3, and DEN4) which are causing the 
DF, DHF, and dengue shock syndrome (DSS). Typically, 
DF begins with a sudden temperature increase accompanied 
by headache, myalgia, macular rash, loss of appetite 
nausea, vomiting, abdominal pain, metallic taste of food, 
change in psychological state, and moderate thrombocytopenia 
[2, 20, 22, 41]. If early clinical management or 
appropriate fluid therapy was not provided, DF will progress 
to DHF. The progress of DHF begins when the fever 
subsided or known as defervescence of the fever. DHF is 
an infection associated with an increase in microvascular 
permeability, a decrease in plasma volume, and in severe 
forms hypotension and shock. If the appropriate therapy 
still not provided, circulatory failure will occur and lead to 
the DSS. DSS is fatal stage manifested by rapid and weak 
pulse and narrow pulse pressure [41]. Therefore, delay in 
the fluid therapy management will lead to progress of the 
dengue disease to the maximum stage (DSS) and may 
cause fatality to the dengue patient. 
 Accurate diagnosis in time and monitoring of severity of 
any dengue infection is needed in order to identify the 
severity of the disease and providing the appropriate 
treatment. In order to treat and control the dengue disease, 
many strategies have been developed and promoted. Two 
conventional techniques have been used to diagnose and to 
monitor the risk in DHF patients. The first technique is 
observing the onset and progression of plasma leakage by 
measuring the total increase in hematocrit (HCT) or the 
hemoglobin (Hb) concentration [15, 19, 20, 41]. The 
advantages of this method not only diagnose the DF but it 
can distinguish the DHF [14, 32, 41]. The second technique 
is to monitor the dengue patients’ platelet (PLT) counts and 
liver function [28]. Even though those techniques can give 
accurate diagnoses, they are time consuming, invasive, and 
may harm the patients [20, 21]. The reasons behind this as 
follow: those techniques require frequent blood taking 
which may cause further injury to the subcutaneous tissue 
and potentially hazardous to the DHF patients. Moreover, 
monitoring of the patients can be done by admitting and 
hospitalizing the patients. However, admitting and hospitalizing 
the patient cannot be arbitrarily or based on 
uncertain identification due to the huge number of the 
dengue patients in the country [20]. 
 Recently, several studies were conducted to achieve 
accurate diagnosis without facing the above-mentioned 
drawbacks. Ibrahim et al. [20] applied bioelectrical impedance 
analysis (BIA) technique to monitor and classify the 
daily risk in DHF patients. Significant outcome was 
attained by using this technique and proved that the 
capability of the BIA to classify the daily risk of DHF 
patients. Another study [21] has reveals the non-invasive 
system for predicting the day of defervescence of fever in 
dengue patients using artificial neural network (ANN). 
Clinical symptoms and signs are used as inputs to the 
ANN. Accordingly, 90% prediction accuracy was 
achieved for predicting the day of defervescence of fever 
in dengue patients. Recently, Faisal et al. [6] employed 
self organized map clustering technique instead of the 
conventional statistical method to identify the risk criteria 
for classifying risk in the dengue patients. 
 This paper focuses on the diagnosis of risk classification 
in the dengue patients utilizing the BIA and a multilayer 
feed-forward neural network (MFNN) techniques. 
 
Methodology 
 The procedures for designing the dengue risk diagnose 
system shows in Fig. 1. 
Clinical data 
 Database comprises of 223 healthy subjects (158 females 
and 65 males) and 207 (90 females and 115 males) serologically 
[5, 27] confirmed dengue patients during their 
hospitalization were prospectively studied. The dengue 
database was divided into blood investigation and BIA 
data. The blood investigation consists of 27 parameters 
such as PLT, HCT, aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), and Hb [18, 20]. The 
blood investigation and the BIA data were taken for 5 days 
with reference to the day the fever subsided. Fever day ?0 
is defined as the day the fever subsided, i.e., when the body 
temperature fell below 37.5_C. Fever days after fever day 
?0 are fever days ?1 and onwards [18, 20]. The blood 
measurement was taken from fever day ?0 until the fever 
day ?4 (fourth day after fever subsided). The BIA database 
comprises of patient information and 17 BIA parameters including the resistance, reactance, body capacitance (BC), 
fat mass, intracellular water, etc. 
 
BIA 
 BIA is an in vivo technique involved the application of a 
small average constant current of less than 1 mA at a single 
frequency of 50 kHz through the human body, and measuring 
the body’s bioelectrical tissue conductivity (BETC) 
parameters, namely, R, phase angle (a), BC, and capacitive 
reactance (Xc) via four surface electrodes [35]. Previous 
studies [19, 20, 22] shown that single frequency technique 
is able to give good results in dengue patients. Two electrodes 
were placed on the patient’s right hand, one at the 
base of the knuckles and another slightly above the wrist 
joint. Another two electrodes were placed on the right foot; 
one nears the base of the toes and the other slightly above 
the ankle joint. A constant current was applied to the base 
of the knuckles and base of the toes, and the voltage signal 
was picked up by the other two sensor electrodes (slightly 
above the ankle and wrist joint). The voltage drop will 
determine the resistance and reactance (Xc) of the whole 
body. This data can then be converted to estimate the 
extracellular water (ECW), intracellular water, fat free 
mass (FFM), and fat mass through regression equations. 
 
Risk quantification 
 In this study, the severities of dengue risk criteria were 
determined based on the following blood investigations 
[18, 20, 41]: 
i. PLT count is less than or equal to 30,000 cells per 
mm3 [4, 18] 
ii. HCT increase by more than or equal to 20% [41] 
iii. AST and ALT levels rose by fivefold the normal 
upper limit for AST and ALT [18, 26]. 
The risk quantification was performed on daily basis 
where blood investigations of the patients were evaluated 
for each day. Based on the blood investigation, the patients 
were then divided into two groups [18, 20]: 
i. Group 2 (Lower risk group) accounted for the DHF 
patient who did not experienced any of the defined risk 
criteria, or experienced only 1 of the 3 risk criteria. 
ii. Group 3 (Higher risk group) accounted for DHF 
patient who experienced 2 or more risk criteria. 
The dengue patients were then classified according to 
their groups and subsequently, their corresponding BIA 
data were obtained and quantified. The healthy subjects 
were automatically grouped as the control group (Group 1) 
with no past medical history and no blood investigations 
evaluated. 
Pre-processing of ANN 
 Database preparation involves parameter selection, data 
massaging, and data grouping. 
Parameter selection 
 In the parameter selection phase from the BIA database 
only three parameters were selected to be the input of the 
MFNN. The input parameters are: day of fever, gender, and 
reactance values. The selection of these parameters was 
based on multi-logistic analysis [18]. The quantified risk 
was assigned as the network target. 
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